NextCure Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . NextCure
NXTC Stock  USD 13.60  0.32  2.41%   
NextCure's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing NextCure's valuation are provided below:
Gross Profit
-54.2 M
Market Capitalization
46.6 M
Enterprise Value Revenue
1.623
Earnings Share
(23.81)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental ratios for NextCure, which can be analyzed and compared to other ratios and to its peers in the industry. Investors should ensure to check all of NextCure's last-minute performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of January 5, 2026, Market Cap is expected to decline to about 23.6 M. The current year's Enterprise Value is expected to grow to about (242.5 K)
Check NextCure financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NextCure's main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Depreciation And Amortization of 3.2 M or Interest Expense of 6.4 M, as well as many indicators such as Price To Sales Ratio of 14.65, Dividend Yield of 0.0 or PTB Ratio of 0.31. NextCure financial statements analysis is a perfect complement when working with NextCure Valuation or Volatility modules.
  
Build AI portfolio with NextCure Stock
Check out the analysis of NextCure Correlation against competitors.
For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.

NextCure Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets69.1 M72.8 M102.6 M
Slightly volatile
Short and Long Term Debt Total4.7 M6.8 M3.2 M
Slightly volatile
Other Current Liabilities4.1 M3.9 M2.8 M
Slightly volatile
Total Current Liabilities9.8 M11 M6.7 M
Slightly volatile
Other Liabilities768.6 K809.1 K2.8 M
Very volatile
Property Plant And Equipment Net14.1 M10 M11.6 M
Slightly volatile
Accounts Payable3.2 M6.2 M2.4 M
Slightly volatile
Cash29 M25 M23.7 M
Pretty Stable
Non Current Assets Total15.9 M10.4 M12.5 M
Slightly volatile
Non Currrent Assets Other362.7 K381.8 K559.6 K
Slightly volatile
Long Term Debt1.6 M2.1 M1.2 M
Slightly volatile
Cash And Short Term Investments58.7 M61.8 M88.1 M
Slightly volatile
Common Stock Total Equity24.4 K32.2 K19 K
Slightly volatile
Common Stock Shares Outstanding2.3 M2.7 M2.1 M
Slightly volatile
Long Term Debt Total1.6 M2.1 M1.2 M
Slightly volatile
Liabilities And Stockholders Equity69.1 M72.8 M102.6 M
Slightly volatile
Non Current Liabilities Total5 M5.2 M33.2 M
Slightly volatile
Capital Surpluse305.3 M495.4 M195.8 M
Slightly volatile
Other Current Assets4.2 M3.3 M2.6 M
Slightly volatile
Total Liabilities13.2 M13.8 M39.7 M
Slightly volatile
Property Plant And Equipment Gross24.1 M36.6 M18 M
Slightly volatile
Short and Long Term Debt1.1 M1.9 M978.8 K
Slightly volatile
Total Current Assets61.4 M64.6 M90.7 M
Slightly volatile
Net Working Capital53.2 M56 M84.2 M
Slightly volatile
Short Term Debt737.9 K716.4 K703.4 K
Slightly volatile
Common Stock26 K32.2 K19.1 K
Slightly volatile
Property Plant Equipment13.8 M13.7 M11.6 M
Slightly volatile
Capital Stock28 K32.2 K19.2 K
Slightly volatile
Non Current Liabilities Other947.4 K594.9 K1.9 M
Slightly volatile
Net Receivables480 K270 K644.1 K
Slightly volatile

NextCure Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.2 M3.3 M2 M
Slightly volatile
Selling General Administrative15.2 M18.1 M9.5 M
Slightly volatile
Other Operating Expenses57.8 M68.7 M38.6 M
Slightly volatile
Research Development42.3 M47.7 M28.7 M
Slightly volatile
Cost Of Revenue2.4 M2.6 M3.6 M
Pretty Stable
Total Operating Expenses53.1 M68.7 M36.3 M
Slightly volatile
Reconciled Depreciation3.6 M3.3 M2.2 M
Slightly volatile
Total Other Income Expense Net2.8 M4.7 M1.7 M
Slightly volatile
Interest Income3 M3.4 M3.7 M
Slightly volatile
Non Operating Income Net Other1.9 M1.1 M3.5 M
Slightly volatile
Selling And Marketing Expenses2.9 M3.3 M3.6 M
Slightly volatile

NextCure Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock171 K180 K33.1 M
Pretty Stable
Stock Based Compensation6.1 M7.3 M3.4 M
Slightly volatile
Begin Period Cash Flow11.2 M11.8 M20 M
Pretty Stable
Other Cashflows From Financing Activities89.8 K94.5 K22.1 M
Slightly volatile
Depreciation3.6 M3.3 M2.2 M
Slightly volatile
Capital Expenditures405.3 K426.6 K5.3 M
Slightly volatile
End Period Cash Flow30 M25 M24.7 M
Pretty Stable
Change To Netincome11.6 M11 M4.3 M
Slightly volatile
Issuance Of Capital Stock33.3 K35.1 K78.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio14.6515.4287.6532
Slightly volatile
Stock Based Compensation To Revenue0.260.320.3129
Slightly volatile
Capex To Depreciation0.180.197.3939
Slightly volatile
EV To Sales13.2213.9284.4121
Slightly volatile
Payables Turnover0.660.480.6651
Slightly volatile
Sales General And Administrative To Revenue1.250.881.2403
Slightly volatile
Research And Ddevelopement To Revenue4.112.394.1653
Slightly volatile
Capex To Revenue0.460.370.455
Slightly volatile
Cash Per Share32.1733.8646.6552
Slightly volatile
Days Payables Outstanding7457843.5 K
Pretty Stable
Net Debt To EBITDA0.440.460.8149
Very volatile
Current Ratio6.416.7510.4284
Slightly volatile
Capex Per Share0.220.232.754
Slightly volatile
Revenue Per Share5.848.786.5832
Slightly volatile
Interest Debt Per Share1.52.31.3164
Slightly volatile
Debt To Assets0.06950.06620.0449
Pretty Stable
Days Of Payables Outstanding7457843.5 K
Pretty Stable
Ebt Per Ebit1.051.070.9808
Very volatile
Quick Ratio6.416.7510.4329
Slightly volatile
Net Income Per E B T0.740.840.9127
Slightly volatile
Cash Ratio4.253.333.3711
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.191.161.3446
Slightly volatile
Fixed Asset Turnover0.781.270.8457
Slightly volatile
Debt Ratio0.06950.06620.0449
Pretty Stable
Price Sales Ratio14.6515.4287.6532
Slightly volatile
Asset Turnover0.03630.06570.0379
Slightly volatile
Gross Profit Margin0.80.90.9786
Slightly volatile

NextCure Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap23.6 M24.8 M319.5 M
Slightly volatile

NextCure Fundamental Market Drivers

NextCure Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About NextCure Financial Statements

NextCure stakeholders use historical fundamental indicators, such as NextCure's revenue or net income, to determine how well the company is positioned to perform in the future. Although NextCure investors may analyze each financial statement separately, they are all interrelated. For example, changes in NextCure's assets and liabilities are reflected in the revenues and expenses on NextCure's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in NextCure. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue149.5 K142 K
Cost Of Revenue2.6 M2.4 M
Stock Based Compensation To Revenue 0.32  0.26 
Sales General And Administrative To Revenue 0.88  1.25 
Research And Ddevelopement To Revenue 2.39  4.11 
Capex To Revenue 0.37  0.46 
Revenue Per Share 8.78  5.84 
Ebit Per Revenue(1.66)(1.74)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc
When determining whether NextCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NextCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nextcure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nextcure Stock:
How To Invest In NextCure
Details
Is NextCure Stock a good investment?
Details
What is NextCure's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of NextCure Correlation against competitors.
For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(23.81)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.58)
Return On Equity
(1.17)
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY